Base de dados : MEDLINE
Pesquisa : A01.941.500 [Categoria DeCS]
Referências encontradas : 3833 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 384 ir para página                         

  1 / 3833 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29211700
[Au] Autor:Kim MJ; Kim JH; Jeon HS; Wee WR; Hyon JY
[Ad] Endereço:*Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea; and†Department of Ophthalmology, Seoul National University Bundang Hospital, Seongnam, Korea.
[Ti] Título:Effect of Histocompatibility Y Antigen Matching on Graft Survival in Primary Penetrating Keratoplasty.
[So] Source:Cornea;37(1):33-38, 2018 Jan.
[Is] ISSN:1536-4798
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To investigate the influence of histocompatibility Y (H-Y) antigen matching on corneal graft survival in primary penetrating keratoplasty (PK). METHODS: Medical records of patients who underwent primary PK at Seoul National University Bundang Hospital between June 2005 and October 2015 were retrospectively analyzed. The eyes were classified into 2 groups: H-Y-compatible (115 eyes) and H-Y-incompatible (23 eyes). The H-Y-compatible group included donor/recipient combinations of male/male (57 eyes), female/male (44 eyes), and female/female (14 eyes). The H-Y-incompatible group included the male/female (23 eyes) combination alone. A subgroup analysis of low- and high-risk patients according to preoperative diagnoses was also performed. Survival analysis was conducted using the Kaplan-Meier method; differences between groups were assessed with a log-rank test. RESULTS: A total of 138 eyes from 136 patients (age: 58 ± 18 years) were enrolled. Rejection-free graft survival and graft survival were not significantly different between H-Y-compatible and H-Y-incompatible groups (χ = 0.4, P = 0.548; χ = 1.9; P = 0.17, respectively). Preoperative diagnoses of high-risk cases included those with corneal perforation or thinning (8.7%) and infectious keratitis (7.2%). Low-risk cases included corneal opacity (50.0%), bullous keratopathy (25.4%), keratoconus (5.8%), and corneal dystrophy (2.9%). In the high-risk group, rejection-free graft survival rate was significantly higher in the H-Y-compatible group (χ = 3.9, P = 0.049). CONCLUSIONS: H-Y antigen matching does not influence graft rejection and failure in cases of primary PK. However, matching the H-Y antigen could help reduce graft rejection, especially in preoperatively high-risk patients.
[Mh] Termos MeSH primário: Doenças da Córnea/cirurgia
Sobrevivência de Enxerto/imunologia
Antígeno H-Y/imunologia
Ceratoplastia Penetrante
[Mh] Termos MeSH secundário: Idoso
Aloenxertos
Feminino
Rejeição de Enxerto/diagnóstico
Teste de Histocompatibilidade
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (H-Y Antigen)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE
[do] DOI:10.1097/ICO.0000000000001394


  2 / 3833 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28466385
[Au] Autor:Atilla E; Atilla PA; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Akay BN; Sanli H; Gurman G; Ozcan M
[Ad] Endereço:BMT Unit, Department of Hematology, Cebeci Hospital, School of Medicine, Ankara University, Dikimevi, 06590, Ankara, Turkey. erdenatilla@gmail.com.
[Ti] Título:Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).
[So] Source:Int J Hematol;106(3):426-430, 2017 Sep.
[Is] ISSN:1865-3774
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Cutaneous T cell lymphoma is a heterogeneous group of lymphoproliferative disorders with different clinical behavior and prognosis in which malignant T cells accumulate in the skin. In the relapsed/refractory stage, treatment strategy varies depending on clinical perspective. We retrospectively evaluated advanced stage relapse or refractory mycosis fungoides and Sezary syndrome patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our hospital. The overall response rate was 25%, while the disease progressed and relapsed after transplant in 38% of patients. Allo-HSCT may be a reasonable treatment option in the relapsed/refractory stage.
[Mh] Termos MeSH primário: Aloenxertos
Transplante de Células-Tronco Hematopoéticas
Micose Fungoide/terapia
Síndrome de Sézary/terapia
Neoplasias Cutâneas/terapia
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
Meia-Idade
Recidiva Local de Neoplasia
Estudos Retrospectivos
Neoplasias Cutâneas/reabilitação
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1007/s12185-017-2245-x


  3 / 3833 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29157615
[Au] Autor:Jaccard A
[Ad] Endereço:Department of Clinical Hematology, Reference Center for AL Amyloidosis, CHU, 2 Avenue ML King, Limoges 87000, France. Electronic address: arnaud.jaccard@chu-limoges.fr.
[Ti] Título:POEMS Syndrome: Therapeutic Options.
[So] Source:Hematol Oncol Clin North Am;32(1):141-151, 2018 02.
[Is] ISSN:1558-1977
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Treatment of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome should be directed at the underlying plasma cell clone with risk-adapted therapy based on the extent of the plasma cell disorder. Radiation therapy is effective for patients with a localized presentation, without bone marrow involvement, and 1 to 3 bone lesions. Patients with disseminated disease should receive, preferably, high-dose chemotherapy with peripheral blood transplantation. Low-dose melphalan and dexamethasone or new agents used in myeloma are also effective. The most promising agent is lenalidomide, which could be given before high-dose therapy or radiation to get rapid neurologic responses.
[Mh] Termos MeSH primário: Síndrome POEMS/terapia
Transplante de Células-Tronco de Sangue Periférico
Talidomida/análogos & derivados
[Mh] Termos MeSH secundário: Aloenxertos
Seres Humanos
Síndrome POEMS/diagnóstico
Síndrome POEMS/patologia
Radioterapia
Talidomida/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
4Z8R6ORS6L (Thalidomide); F0P408N6V4 (lenalidomide)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171122
[St] Status:MEDLINE


  4 / 3833 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461213
[Au] Autor:Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi RJ; Hematti P; Kamble RT; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
[Ad] Endereço:Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts. Electronic address: lynda_vrooman@dfci.harvard.edu.
[Ti] Título:Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age.
[So] Source:Biol Blood Marrow Transplant;23(8):1327-1334, 2017 Aug.
[Is] ISSN:1523-6536
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Very young children undergoing hematopoietic cell transplantation (HCT) are a unique and vulnerable population. We analyzed outcomes of 717 patients from 117 centers who survived relapse free for ≥1 year after allogeneic myeloablative HCT for hematologic malignancy at <3 years of age, between 1987 and 2012. The median follow-up was 8.3 years (range, 1.0 to 26.4 years); median age at follow-up was 9 years (range, 2 to 29 years). Ten-year overall and relapse-free survival were 87% (95% confidence interval [CI], 85% to 90%) and 84% (95% CI, 81% to 87%). Ten-year cumulative incidence of relapse was 11% (95% CI, 9% to 13%). Of 84 deaths, relapse was the leading cause (43%). Chronic graft-versus-host-disease 1 year after HCT was associated with increased risk of mortality (hazard ratio [HR], 2.1; 95% CI, 1.3 to 3.3; P = .0018). Thirty percent of patients experienced ≥1 organ toxicity/late effect >1 year after HCT. The most frequent late effects included growth hormone deficiency/growth disturbance (10-year cumulative incidence, 23%; 95% CI, 19% to 28%), cataracts (18%; 95% CI, 15% to 22%), hypothyroidism (13%; 95% CI, 10% to 16%), gonadal dysfunction/infertility requiring hormone replacement (3%; 95% CI, 2% to 5%), and stroke/seizure (3%; 95% CI, 2% to 5%). Subsequent malignancy was reported in 3.6%. In multivariable analysis, total body irradiation (TBI) was predictive of increased risk of cataracts (HR, 17.2; 95% CI, 7.4 to 39.8; P < .001), growth deficiency (HR, 3.5; 95% CI, 2.2 to 5.5; P < .001), and hypothyroidism (HR, 5.3; 95% CI, 3.0 to 9.4; P < .001). In summary, those who survived relapse free ≥1 year after HCT for hematologic malignancy at <3 years of age had favorable overall survival. Chronic graft-versus-host-disease and TBI were associated with adverse outcomes. Future efforts should focus on reducing the risk of relapse and late effects after HCT at early age.
[Mh] Termos MeSH primário: Doença Enxerto-Hospedeiro/mortalidade
Doença Enxerto-Hospedeiro/terapia
Neoplasias Hematológicas/mortalidade
Neoplasias Hematológicas/terapia
Transplante de Células-Tronco Hematopoéticas
[Mh] Termos MeSH secundário: Fatores Etários
Aloenxertos
Pré-Escolar
Doença Crônica
Intervalo Livre de Doença
Feminino
Seguimentos
Seres Humanos
Lactente
Masculino
Taxa de Sobrevida
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  5 / 3833 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29289267
[Au] Autor:Ibrahim ME; Bana EE; El-Kerdasy HI
[Ad] Endereço:Internal Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt. Electronic address: tantawy_d@yahoo.com.
[Ti] Título:Role of Bone Marrow Derived Mesenchymal Stem Cells and the Protective Effect of Silymarin in Cisplatin-Induced Acute Renal Failure in Rats.
[So] Source:Am J Med Sci;355(1):76-83, 2018 Jan.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cisplatin is a highly effective antitumor agent whose clinical application is limited by its nephrotoxicity, which is associated with high mortality and morbidity rates. We aimed to study the protective role of silymarin and mesenchymal stem cells as a therapeutic tool of cisplatin nephrotoxicity. MATERIALS AND METHODS: We injected rats with cisplatin in a dose of 5mg/kg body weight for 5 days to induce acute renal failure (ARF). Silymarin was administrated 6 hours before cisplatin injection and mesenchymal stem cells were injected 24 hours after cisplatin-induced ARF. RESULTS: We assessed the ARF biochemically by elevation of kidney function tests and histopathologically by an alteration of the histological architecture of the renal cortex in the form of shrinkage of glomeruli, lobulated tufts and glomerular hypertrophy with narrowing capsular space. The tubules showed extensive tubular degeneration with cellular hyaline materials and debris in the lumen of the renal tubules. The renal blood vessels appeared sclerotic with marked thickened walls. When silymarin was given in different doses before cisplatin, it decreased the toxic effect of cisplatin in the kidney but sclerotic blood vessels remained. Injection of mesenchymal stem cells in rats with cisplatin-induced ARF improved the histopathological effects of cisplatin in renal tissues and kidney function tests were significantly improved. CONCLUSIONS: There was a significant improvement in kidney function tests and renal histopathology by using silymarin as protective mechanism in cisplatin-induced ARF. Administration of mesenchymal stem cells denoted a more remarkable therapeutic effect in ARF.
[Mh] Termos MeSH primário: Lesão Renal Aguda
Células da Medula Óssea/metabolismo
Cisplatino/efeitos adversos
Transplante de Células-Tronco Mesenquimais
Células Mesenquimais Estromais/metabolismo
Silimarina/farmacologia
[Mh] Termos MeSH secundário: Lesão Renal Aguda/induzido quimicamente
Lesão Renal Aguda/metabolismo
Lesão Renal Aguda/patologia
Lesão Renal Aguda/terapia
Aloenxertos
Animais
Células da Medula Óssea/patologia
Cisplatino/farmacologia
Modelos Animais de Doenças
Masculino
Células Mesenquimais Estromais/patologia
Ratos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Silymarin); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180101
[St] Status:MEDLINE


  6 / 3833 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29289266
[Au] Autor:Trop-Steinberg S; Azar Y
[Ad] Endereço:Faculty of Life and Health Sciences (ST-S), JCT Lev Academic Institute, Jerusalem, Israel. Electronic address: shivtia@g.jct.ac.il.
[Ti] Título:Is Myc an Important Biomarker? Myc Expression in Immune Disorders and Cancer.
[So] Source:Am J Med Sci;355(1):67-75, 2018 Jan.
[Is] ISSN:1538-2990
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The proto-oncogene Myc serves as a paradigm for understanding the dynamics of transcriptional regulation. Myc protein has been linked to immune dysfunction, cancer development and neoplastic transformation. We review recent research regarding functions of Myc as an important modulator in immune disorders, postallogeneic hematopoietic stem cell transplantation (HSCT) and several cancers. Myc overexpression has been repeatedly linked to immune disorders and specific cancers, such as myasthenia gravis, psoriasis, pemphigus vulgaris, atherosclerosis, long-term allogeneic survival among HSCT patients, (primary) inflammatory breast cancer, (primary) ovarian carcinoma and hematological malignancies: acute myeloid leukemia, chronic myelogenous leukemia, Hodgkin's lymphoma and diffuse large B-cell lymphoma. However, decreased expression of Myc has been observed in HSCT patients who did not survive. Understanding impaired or inappropriate expression of Myc may present a path for the discovery of new targets for therapeutic applications.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/biossíntese
Regulação Neoplásica da Expressão Gênica
Doenças do Sistema Imune/metabolismo
Neoplasias/metabolismo
Proteínas Proto-Oncogênicas c-myc/biossíntese
[Mh] Termos MeSH secundário: Aloenxertos
Intervalo Livre de Doença
Transplante de Células-Tronco Hematopoéticas
Seres Humanos
Doenças do Sistema Imune/patologia
Doenças do Sistema Imune/terapia
Neoplasias/patologia
Neoplasias/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (MYC protein, human); 0 (Proto-Oncogene Proteins c-myc)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180101
[St] Status:MEDLINE


  7 / 3833 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776929
[Au] Autor:Sawinski D
[Ad] Endereço:Department of Medicine, Renal Electrolyte and Hypertension Division, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA, 19104. Electronic address: Deirdre.sawinski@uphs.upenn.edu.
[Ti] Título:Kidney transplantation for HIV-positive patients.
[So] Source:Transplant Rev (Orlando);31(1):42-46, 2017 Jan.
[Is] ISSN:1557-9816
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:HIV+ patients are at increased risk for end-stage renal disease, but HIV infection was once considered a contraindication to renal transplantation. However, contemporary studies from the United States and Europe have now demonstrated that renal transplantation is a safe and effective treatment for end-stage renal disease in HIV patients, with equivalent patient and allograft survival to those uninfected. Broader experience in transplantation in HIV+ patients has identified unique challenges including high rates of acute rejection, delayed graft function, and significant drug-drug interactions. Kidney transplantation in HIV-infected patients is an active area of clinical research and trials of HIV+ to HIV+ transplantation in the United States are underway.
[Mh] Termos MeSH primário: Infecções por HIV/epidemiologia
Falência Renal Crônica/epidemiologia
Falência Renal Crônica/cirurgia
Transplante de Rim/efeitos adversos
Transplante de Rim/métodos
[Mh] Termos MeSH secundário: Aloenxertos
Terapia Antirretroviral de Alta Atividade/métodos
Comorbidade
Seleção do Doador
Feminino
Rejeição de Enxerto
Sobrevivência de Enxerto
Infecções por HIV/diagnóstico
Infecções por HIV/tratamento farmacológico
Seres Humanos
Falência Renal Crônica/diagnóstico
Masculino
Complicações Pós-Operatórias/epidemiologia
Complicações Pós-Operatórias/fisiopatologia
Prognóstico
Medição de Risco
Doadores de Tecidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  8 / 3833 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27771937
[Au] Autor:Huang YC; Xiao J; Leung WY; Lu WW; Hu Y; Luk KD
[Ad] Endereço:Department of Orthopaedics and Traumatology, The University of Hong Kong, 5/F Professor Block, Queen Mary Hospital, Pokfulam, Hong Kong SAR, China.hrmoldk@hku.hk.
[Ti] Título:Lumbar intervertebral disc allograft transplantation: healing and remodelling of the bony structure.
[So] Source:Eur Cell Mater;32:216-227, 2016 10 19.
[Is] ISSN:1473-2262
[Cp] País de publicação:Scotland
[La] Idioma:eng
[Ab] Resumo:Previous human study suggested that fresh-frozen intervertebral disc allograft transplantation can relieve neurological symptoms and restore segmental kinematics. Before wide clinical application, research into the pathophysiology of the postoperative disc allograft is needed. One important question that remains to be answered in disc allografting is the healing process of the host-graft interface and the subsequent change of the endplates. With the goat model for lumbar disc allografting, histology, micro-computed tomography analysis, scanning electron microscopy and energy-dispersive X-ray spectroscopy mapping were applied to evaluate the healing of the host-graft interfaces, the remodelling of subchondral bone, and the changes of the bony and cartilaginous endplates after transplantation. It was found that healing of the host-graft interfaces started at 1.5 months and was completed at 6 months by natural remodelling. This bony remodelling was also noted in the subchondral bone area after 6 months. The bony endplate was well preserved initially, but was gradually replaced by trabecular bone afterwards; on the other hand, the cartilaginous endplate became atrophic at 6 months and nearly disappeared at the final follow-up. Collectively, after intervertebral disc allograft transplantation, bony healing and remodelling were seen which ensured the stability and mobility of the disc-transplanted segment, but the integrity of bony and cartilaginous endplates was gradually lost and nearly disappeared finally.
[Mh] Termos MeSH primário: Aloenxertos/transplante
Disco Intervertebral/transplante
Vértebras Lombares/transplante
Cicatrização
[Mh] Termos MeSH secundário: Animais
Cartilagem/diagnóstico por imagem
Cartilagem/patologia
Cabras
Disco Intervertebral/diagnóstico por imagem
Disco Intervertebral/ultraestrutura
Vértebras Lombares/diagnóstico por imagem
Vértebras Lombares/ultraestrutura
Masculino
Espectrometria por Raios X
Microtomografia por Raio-X
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  9 / 3833 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29252743
[Au] Autor:Riff AJ; Gross CE; Foucher KC; Kuo KN; Gitelis S
[Ad] Endereço:Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, Illinois.
[Ti] Título:Acetabular Osteoarticular Allograft After Ewing Sarcoma Resection: A 15-Year Follow-up: A Case Report.
[So] Source:JBJS Case Connect;6(4):e89, 2016 Oct-Dec.
[Is] ISSN:2160-3251
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:CASE: A 4-year-old girl with Ewing sarcoma of the periacetabular region had been treated with neoadjuvant chemotherapy followed by resection and osteoarticular allograft reconstruction with an adult hemipelvis. At 15 years postoperatively, she remained disease-free with remarkable functionality. She had minimal groin pain and could walk an unlimited distance. Radiographs demonstrated union at the anastomotic junctions. The allograft, which had been considerably oversized 15 years ago, was now identical in size to the contralateral ilium. CONCLUSION: Osteoarticular allograft remains one of the best reconstructive options following hemipelvectomy in the pediatric population because of its potential durability and its capacity to restore pelvic stability and preserve functionality.
[Mh] Termos MeSH primário: Acetábulo/transplante
Neoplasias Ósseas/cirurgia
Sarcoma de Ewing/cirurgia
[Mh] Termos MeSH secundário: Aloenxertos
Cartilagem Articular/cirurgia
Desenvolvimento Infantil
Pré-Escolar
Seres Humanos
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.2106/JBJS.CC.16.00071


  10 / 3833 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29365389
[Au] Autor:Cui PC
[Ad] Endereço:Department of Otorhinolaryngology Head and Neck Surgery, Tangdu Hospital, Fourth Military Medical University, Xi'an 710038, China.
[Ti] Título:[Advances in tracheal transplantation].
[So] Source:Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi;53(1):73-75, 2018 Jan 07.
[Is] ISSN:1673-0860
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:The length of tracheal defect or stenosis exceeded 5 cm could not be treated by simple resection and end-to-end anastomosis of the remaining trachea. Various ways of tracheal replacement had appeared sequentially, such as radial forearm free flap with cartilage grafts, tracheal tissue-engineering and tracheal allotransplantation. Among these methods, tracheal allotransplantation displayed a better long-term result. In this review, we are focused on recent advances in tracheal allotransplantation, particularly on revascularization and reepithelialization of graft, as well as on the application of immunosuppressive agents.
[Mh] Termos MeSH primário: Traqueia/transplante
[Mh] Termos MeSH secundário: Aloenxertos
Seres Humanos
Estenose Traqueal/cirurgia
Transplante/tendências
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180125
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.1673-0860.2018.01.019



página 1 de 384 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde